key: cord-0695242-iv67hm9c authors: de la Calle, Cristina; López-Medrano, Francisco; Pablos, José Luis; Lora-Tamayo, Jaime; Calle, Guillermo Maestro-de la; Sánchez-Fernández, Marcos; Fernández-Ruiz, Mario; Asín, María Asunción Pérez-Jacoiste; Caro-Teller, José Manuel; García-García, Rocío; Catalán, Mercedes; Martínez-López, Joaquín; Sevillano, Ángel; Origüen, Julia; Ripoll, Mar; Juan, Rafael San; Lalueza, Antonio; de Miguel, Borja; Carretero, Octavio; Aguilar, Fernando; Gómez, Carlos; Paz-Artal, Estela; Bueno, Héctor; Lumbreras, Carlos; Aguado, José María title: Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study date: 2021-02-13 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.041 sha: 4768b93778ba180af86b3b8a1af7cbd84fbe91f7 doc_id: 695242 cord_uid: iv67hm9c Objetives A subgroup of patients with SARS-CoV-2 infection is considered to develop a cytokine release syndrome and have been treated with tocilizumab, but a significant percentage of patients evolve. Our objective was to determine the usefulness of anakinra as rescue treatment for patients with tocilizumab-refractory COVID-19 disease. Methods A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a six-point ordinal scale, from baseline to day 21. Results The study included 20 cases and 20 controls (mean age 65.3±12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. In-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P =0.527). Conclusions Treatment with anakinra was not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. As of January 2021, the worldwide outbreak of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), responsible of the viral pneumonia known as COVID-19, have caused more than 94 million infections and 2 million deaths [1]. SARS-CoV-2 infection produces mild symptoms of respiratory tract infection in most individuals but a subgroup of patients with COVID-19 develop a severe disease with acute respiratory distress syndrome (ARDS) and/or multiple organ dysfunction especially affecting the heart, liver and kidneys. In these patients, increased systemic levels of cytokines and chemokines are observed which deleterious role has been hypothesized by similarities with other cytokine release syndromes (CRS) [2] . CRS may occur as part of the clinical picture of hemophagocytic lymphohistiocytosis or macrophage activation syndrome observed after triggering by viral infections, systemic diseases such as adult-J o u r n a l P r e -p r o o f onset Still's disease or the systemic juvenile idiopathic arthritis or after therapeutic immune-activation by CAR T-cells. In these conditions, treatment with IL-1 or IL-6 cytokine antagonists has been found effective [3, 4] . Previous studies have postulated that treating patients with severe COVID and hyperinflammation with immunomodulatory drugs could improve prognosis. Tocilizumab, an IL-6 antagonist, has become the most used drug and several clinical trials have been published in patients with moderate-severe COVID19 to date [5] [6] [7] [8] [9] . Other anti-cytokine strategies have been proposed, including the use of the IL-1 receptor antagonist anakinra, with conflicting results in studies published to date [10] [11] [12] [13] . Nevertheless, the prognosis remains ominous for a subgroup of patients and evidence from randomized controlled trials is still limited. Therefore, the decision of targeting one or another cytokine is still difficult. In our institution, anakinra was prescribed as a rescue therapy for those patients with ARDS in the context of Covid-19 infection that remained in a situation of respiratory failure despite a previous treatment with tocilizumab which was the first election based upon preliminary reports of potential efficacy. To the best of our knowledge, we communicate the first series to analyse the potential effectiveness of anakinra after tocilizumab failure for improving prognosis, in comparison to a historical series of patients of the same hospital that did not receive anakinra in this context. J o u r n a l P r e -p r o o f The study was conducted in the Hospital Universitario "12 de Octubre" in Madrid (Spain). The hospital has 1.300 beds, and it is one of the largest hospitals in the Region of Madrid. It serves a population of 370,000 inhabitants of the South of the city of Madrid. The hospital admitted more than 3.000 patients with COVID-19 between March and May 2020. The study was approved by the Clinical Research Ethics Committee and they granted a waiver of informed consent due to its observational design. We included a prospective cohort of ≥18 years old hospitalised patients with COVID19 severe pneumonia who received anakinra as rescue therapy after not achieving clinical respiratory improvement despite treatment with tocilizumab, from April 6 to May 8, and they were compared with selected controls in a historical cohort of patients treated with tocilizumab from March 18 to May 14. Four of the patients included in this series have been included in previously published series of haematological patients of our centre that received anakinra [14] . In our centre the patients with a confirmed by reverse transcription-PCR on nasopharyngeal swabs SARS-CoV-2 infection or with high clinical suspicion, who presented chest x-ray compatible with COVID-19-pneumonia, oxygen saturation while breathing ambient air of 90% or less and hyperinflammation analytical data (C-reactive protein (CPR) ≥10 mg/dl, ferritin ≥ 500 mg/dl or D-dimers ≥ 1500 ng/ml) were candidates to receive tocilizumab, at dose of 600 mg in a single dose in patients whose weight was ≥ 75 kg or 400 mg in a single dose in patients weighing less than 75 kg. The administration of a second dose within the following 24 hours was indicated according to the criteria of the attending physician. Controls were consecutively selected from the historical cohort of patients admitted to our centre, who had received treatment with tocilizumab. For each case, the first chronologically matching control fulfilling the following criteria was selected: age ±5 years, index score Charlson for comorbidity ± 2 points, same clinical status according the six-point ordinal scale and the same number of days without improvement in oxygen requirements since the first day of treatment with tocilizumab as the corresponding case. Patients and controls were followed up to discharge from hospital or death. Epidemiological data and baseline comorbidities, time between debut of symptoms and inclusion, previous therapies administered and clinical characteristics, laboratory values, respiratory status and radiological features on day 0 were collected from electronic medical records using a standardized case report form, as well as on days 7, 14 and 21 after inclusion. Adverse events potentially attributable to anakinra were also collected. All laboratory and imaging investigations were performed as part of standard of care. Respiratory function was assessed by means of the pulse oximetry oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio, which shows a good correlation with the partial pressure of arterial oxygen (PaO2)/FiO2 ratio (SpO2/FiO2 = 64 + 0.84 x PaO2/FiO2) [16] . Patients and controls were initially treated with supportive care with or without a combination of oral lopinavir-ritonavir (400 mg twice daily for 5 days), hydroxychloroquine ± oral azithromycin (400 mg twice daily for 2 doses on day 1, followed by 200 mg twice daily on days 2-5 plus or minus 500 mg of azithromycin 3-5 days) subcutaneous interferon-β (0.25 mg SC each 48 hours for 14 days), corticosteroids (iv methylprednisolone 0.5 to 1 mg/Kg daily for 3 days or as boluses of 100 to 250 mg daily for 3 days) and antibiotics at the criterion of their physicians in charge and in accordance with the institutional protocol. No patient in the present study received concomitant treatment with remdesivir, as simultaneous treatment with tocilizumab or anakinra as it was one exclusion criterion for the clinical trial with which this drug was used in the hospital at that time. The diagnosis of COVID-19 was made by means of SARS-CoV-2 real time We report quantitative data as mean ± standard deviation (SD) or median with interquartile range (IQR), whereas qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the χ 2 test or fisher's exact test when applicable. Student's t-test or Mann-Whitney U test were applied for continuous variables. The threshold for significance was set at a P-value <0.05. Statistical analysis was performed with SPSS version 25.0 (IBM Corp., Armonk, NY) and graphs were generated with Prism version 6.0 (GraphPad Software Inc., La Jolla, CA). (Table 3) . Six patients (30%) and 7 (35%) had been discharged on day 21 in the anakinra group and in the control group respectively. The mortality rate in-hospital in patients receiving anakinra was 55% vs. 45% in the control group (p= 0.527). Four patients (20%) in the anakinra group and 6 (30%) in the control group developed a thromboembolic event during the hospital stay. Four patients (20%) in the control group presented an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >3-fold the upper limit of the normal range, none in the anakinra group. Three patients (15%) in the anakinra group and 2 patients (10%) in the control group presented some microbiologically documented bacterial infection during the hospital stay; in two of them a nosocomial acquired pneumonia due to Klebsiella pneumonia was diagnosed, and all of them presented a catheter-related bacteraemia, two due to Enterococcus faecalis and the other due to coagulase-negative staphylococci. There is scarce information available about the best approach for patients with COVID-19 with persistent severe disease after tocilizumab therapy. In our institution, the steering committee for immunomodulatory treatment proposed the use of anakinra as a rescue treatment for patients who do not improve their respiratory status after treatment with tocilizumab. IL-1 antagonists including anakinra are the first therapeutic choice in CRS associated with many autoinflammatory disorders, where inflammasome activation seems a key pathogenic element [17] . The complementary or hierarchical roles of IL-1 and IL-6 are unclear in the COVID-19 setting, but an upstream role for IL-1 in the cytokine cascade can be postulated based upon the direct activation effects of conserved SARS coronaviruses protein E on the NLPR3 inflammasome [18] . In our experience, the addition of anakinra to the standard treatment of COVID-19 in our hospital, including tocilizumab for patients with severe inflammatory response, did not provide any benefit in terms of respiratory improvement or mortality reduction. Previous studies have reported an improvement in the prognosis of severe COVID19 patients treated with anakinra [10] [11] [12] 19] although the time elapsed between symptom onset and anakinra treatment initiation was shorter, and the patients had not previously been treated with immunomodulating drugs. Also, anecdotal isolated case reports have communicated the beneficial effect of immunomodulators for severe COVID-19 refractory to treatment with tocilizumab, such as ruxolitinib (a janus kinase inhibitor) [20] and anakinra itself [21] . There are some explanations to justify the negative results of the present study. One possibility is that the therapeutic effect of IL-1 inhibition by anakinra could depend on downstream suppression of IL-6 synthesis and its systemic proinflammatory effects. In this case, no additional effects would be expected in patients previously treated with tocilizumab, which efficiently blocks the IL-6 pathway in COVID-19 as inferred from its potent effect on CRP synthesis in these patients [22] . However, additional markers for macrophage activation in On the other hand, CRS suppression is likely to be more effective in earlier phases, before severe lung damage is established. It has to be highlighted that the median days since symptoms debut to anakinra treatment was 16 days (IQR: [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and 90% of patients in each group presented a PAFI less than 200 on day 0, which reflects the advanced stage of the disease. In addition to this, the high comorbidity of the patients was responsible for that many of them were not potential candidates for ICU admission or mechanical ventilation. This fact definitely influenced the extremely high mortality of our sample compared to other works [24] and could influence the lack of response to treatments. We cannot exclude a potentially benefit of anakinra as a rescue therapy after failure of therapy with tocilizumab when administered to younger patients or at earlier stages of the disease. Another explanation may be the relatively low dose of anakinra selected by the local committee, based upon previous recommendations experience in patients with no-infections systemic inflammatory rheumatological diseases [25] . Since most recommendations are based upon consensus and no randomized trials have been performed, there is remarkable disparity in the recommended dosing [16] . A study [10] involving a moderate-severe COVID19 cohort compared a lowdose anakinra (100 mg subcutaneous twice daily) to a high-dose anakinra cohort (10 mg/kg per day intravenously) and a retrospective control cohort; treatment with anakinra was only beneficial for those patients that received the higher dose. Nevertheless, other studies have obtained favourable results with low doses, similar to those used in our centre [11] . Our study presents several limitations. Firstly, it's a study with a limited number of cases and controls. Secondly, although a great effort has been made to select comparable controls for baseline characteristics and disease severity, bias due to unmeasured confounding cannot be excluded. The single-center design hampers the generalizability of our results to other institutions that might have applied different criteria for the sequential use of tocilizumab and anakinra. Also, a potential beneficial effect of higher doses of anakinra cannot be ruled out. Finally, this study was carried out with patients treated in the first weeks of the pandemic, with high rates of hospital occupancy and limited access to the ICU, therefore, it cannot be ruled out that the prognosis of patients would have been different under other epidemiological context. This is the first study assessing the effectiveness of anakinra as rescue therapy in patients with tocilizumab-refractory severe COVID-19, using a control group for comparison. We could not demonstrate a beneficial effect of anakinra over standard of care in patients not responding positively to tocilizumab treatment. Nevertheless, the blockade of both cytokine pathways, IL-1 and IL-6, is being evaluated in larger series and ongoing clinical trials which will help to clarify its clinical usefulness [26] and the adequate temporal sequence for its use. Clinical features of patients infected with 2019 novel coronavirus in Wuhan Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids Macrophage activation syndrome in the era of biologic therapy Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial Tocilizumab in Hospitalized Patients with COVID-19 Pneumonia Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Targeting the Inflammatory Cascade With Anakinra in Moderate to Severe COVID-19 Pneumonia: Case Series Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia ANA-1): a randomised controlled trial IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 Comparison of the SpO2/FiO2 ratio and the PaO2/FiO2 ratio in patients with acute lung injury or ARDS Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19 Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease Ruxolitinib for tocilizumab-refractory severe COVID-19 infection Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. Reumatol Clin Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 Online ahead of print Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor -anakinra. Respirol Case Rep Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial Age, years [